Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 129,731

Document Document Title
WO/2018/132372A1
Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.  
WO/2018/130943A1
The present invention relates to an oral pharmaceutical composition, particularly a tablet, comprising an active ingredient lurasidone or its pharmaceutically acceptable salt(s) or solvate(s) thereof and one or more pharmaceutical excipi...  
WO/2018/132531A1
Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).  
WO/2018/130140A1
A novel deuterated urea compound, specifically relating to a compound represent by the formula (I), pharmacologically acceptable salts thereof, preparation method therefor, and a pharmaceutical composition containing the compounds. Also ...  
WO/2018/130868A1
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment a...  
WO/2018/130063A1
The present invention provides an (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, which has diffraction peaks when 2θ is 12.423±0.2°, 16.465±0.2°, 17.344±0.2°, 21.889±0.2°, and 25.054±0.2°. The present invention can p...  
WO/2018/130207A1
The present invention pertains to the field of pharmaceutical chemicals, and discloses a 4,4-diphenyl piperidine compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition using the same, and a use thereof. Spec...  
WO/2018/130863A1
The invention relates to promoting authopagy in the treatment or prevention of autophagy related disorders, such as various forms of cancer; neurodegenerative disease, diabetes, immune deficiency, infection by intracellular microbes, tis...  
WO/2018/132738A1
The present disclosure relates to methods of treating cerebral palsy and hypoxic-ischemic brain injury. More particularly, the present disclosure relates to methods of using cord blood or components thereof to treat cerebral palsy and hy...  
WO/2018/132829A1
The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extra...  
WO/2018/130345A1
The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in...  
WO/2018/132791A1
The invention is directed to the treatment of tauopathic neurodegenerative conditions and the underlying processes thereof. Based on the discovery that Rhes acts as a negative regulator of normal tau clearance, the compositions and metho...  
WO/2018/130123A1
The present invention falls within the field of medical chemistry, and relates to a pentacyclic compound as a selective estrogen receptor down-regulator and the use thereof. In particular, provided in the present invention are a compound...  
WO/2018/130124A1
The present invention falls within the field of medical chemistry, and relates to a tricyclic compound as a selective estrogen receptor down-regulator and the use thereof. In particular, provided in the present invention are a compound a...  
WO/2018/131672A1
The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonin nervous system- or dopamine nervous system-related diseases, in particular, mental dysfunction symptoms and other non-...  
WO/2018/130554A1
The present invention relates to a method for obtaining extracellular vesicles derived from mesenchymal stromal cells (MSCs), wherein the extracellular-vesicles are essentially free of vesicles not derived from the MSCs, and wherein the ...  
WO/2018/130865A1
A composition for treating headaches and migraines and methods of using same for preventative use to decrease the frequency, duration and severity of headaches and migraines in children and adults.  
WO/2018/130000A1
Disclosed in the present invention are a self-assembled serially-connected cell-penetrating peptide nano-particulate antibacterial agent capable of penetrating the blood brain barrier, a preparation method therefor, and uses thereof. The...  
WO/2018/132467A1
The present invention provides homing peptides that localize in central nervous system tissue characterized by neuroinflammation and methods of using the same.  
WO/2018/132533A1
Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).  
WO/2018/129722A1
Provided are a new lactic acid bacteria (LAB), Lactobacillus fermentum PS150, and bioactive protein produced by the LAB has advantageous effect in improving mood disorder, enhancing cognitive functions in brain and treating or preventing...  
WO/2018/130549A1
A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-ce...  
WO/2018/129609A1
Compounds of formula (II) are useful in modulating voltage-gated sodium channel activity. Their preparation and use for reducing the severity of convulsant activity in a subject, for example in the treatment of epilepsy, is presented.  
WO/2018/132636A1
The present invention provides a compound having the structure: (Formula I), and a method of inhibiting Glycogen synthase kinase-3 β (GSK-3β) in a subject comprising administering to the subject said compound, so as to thereby inhibit ...  
WO/2018/131662A1
This prophylactic and/or therapeutic agent for diseases associated with AMPA receptors contains a compound represented by formula (I), or a pharmaceutically acceptable salt or solvate thereof. (In the formula, A and Z independently repre...  
WO/2018/130869A1
This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment a...  
WO/2018/130839A1
The present invention relates, to a laminin receptor peptide for use in the treatment of amyotrophic lateral sclerosis (ALS), which is also known as Motor Neurone Disease (MND) and can include Frontotemporal Dementia (FTD). The invention...  
WO/2018/129511A2
The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration an...  
WO/2018/128722A1
Disclosed herein are methods and compositions that can be used to treat and diagnose parkinsonism, for example Parkinson's disease, and uses for the same.  
WO/2018/126673A1
An application of albiflorin or a pharmaceutically acceptable salt thereof as an IDO inhibitor; albiflorin or a pharmaceutically acceptable salt thereof serving as an IDO inhibitor can be used for preparing a drug, food, health product, ...  
WO/2018/127462A1
The present invention relates to anti-gene oligonucleotides adapted to hybridize to DNA in a HTT gene, which are based on locked nucleic acids, phosphorodiamidate morpholino oligomers, (PMO) or equivalent oligonucleotide analogues compri...  
WO/2018/129421A1
The purpose of this study and report was to evaluate GM6 as a Parkinson's Disease (PD) drug candidate and the possible mechanism of action and pathways. We show that GM6 rescues in vitro survival of salsolinol-treated SH-SY5Y cells and r...  
WO/2018/129395A1
The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.  
WO/2018/127519A1
The present invention is based on antibodies which are both highly specific for hyperphosphorylated pathogenic P-S396 tau and highly specific for labelled sections of the human retina, as well as to methods of using these antibodies and ...  
WO/2018/127828A1
The present invention relates to a therapeutic method using a tolerogenic peptide. In particular, the invention relates to a dosage regimen fora tolerogenic peptide. The therapeutic method can be used to treat or prevent conditions assoc...  
WO/2018/127748A1
The present invention relates to a pharmaceutical composition, characterized in that it comprises, as active ingredient, a combination of d-limonene, lupeol and a pharmaceutically active agent selected from cinnamaldehyde, epicatechin, m...  
WO/2018/129405A1
Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer...  
WO/2018/129363A1
A method of delivering nicotine to treat dyskinesia, such as Levodopa induced dyskinesia (LID), includes delivering a first dose of nicotine to a patient using a transdermal delivery device and delivering a second dose of nicotine to the...  
WO/2018/127088A1
It relates to a lurasidone solid dispersion and a preparation method, wherein the method comprises melting treatment of a mixture containing lurasidone, a medicinal hot melt carrier, optionally an acidic regulator and plasticizer in orde...  
WO/2018/129315A1
The invention relates to methods and compositions comprising a TRP channel or ASIC channel activator for preventing or treating a disease, disorder, or condition described herein.  
WO/2018/129097A1
Synthetic cannabinoid medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. T...  
WO/2018/125716A1
The application is directed to compounds of formula (I): and pharmaceutically acceptable salts, radiolabeled isomers, solvates, or hydrates thereof, wherein R1, R2, R3, X, and n are defined as set forth in the specification. The applicat...  
WO/2018/122409A1
Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions...  
WO/2018/124283A1
The present invention addresses the problem of providing a solid pharmaceutical composition that suppresses the bitter taste characteristic of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and has excellent ...  
WO/2018/124282A1
The present invention addresses the problem of providing a pharmaceutical composition that contains a high concentration of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and masks the bitter taste thereof, a...  
WO/2018/124277A1
[Problem] To provide a pharmaceutical composition that contains a fusion protein of an antibody and a lysosomal enzyme as an active ingredient and is stable enough to be distributed on the market. [Solution] A lyophilized preparation tha...  
WO/2018/120437A1
Provided are an adult pluripotent olfactory stem cell and a separation method therefor and the use thereof. The isolated adult pluripotent olfactory stem cell expresses the B cell-specific Moloney murine leukemia virus insertion site 1.  
WO/2018/121770A1
An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. The com...  
WO/2018/124284A1
The present invention addresses the problem of providing a solid pharmaceutical composition that suppresses both the bitter taste and the bitter aftertaste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof. T...  
WO/2018/123982A1
The microneedle device according to the present invention comprises: a substrate, a microneedle disposed on the substrate, and a coating formed on the microneedle, the coating containing dexmedetomidine or a pharmaceutically acceptable s...  

Matches 1 - 50 out of 129,731